Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Corsini

Showing results (1-10 of 200) with videos related to

Pageof 20
Sort By:
Cardiovascular Drugs and Therapy|February 3, 2006
Statin-related muscle complaints: an underestimated riskAlberto Corsini
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 6, 2019
Statin-associated muscle symptoms: is Proprotein convertase subtilisin/kexin type 9 inhibitors a therapeutic option?Alberto Corsini
Expert Opinion on Pharmacotherapy|April 16, 2025
Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidenceAlberto Corsini
Cardiovascular Drugs and Therapy|October 24, 2003
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular riskAlberto Corsini
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 22, 2016
Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events: the importance of keeping constant low cholesterol levelsAlberto Corsini
Renal Failure|June 17, 2005
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantationAlberto Corsini, Hallvard Holdaas
Journal of Clinical Pharmacology|February 26, 2013
Drug-induced liver injury: the role of drug metabolism and transportAlberto Corsini, Michele Bortolini
Drugs|August 5, 2011
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differencesRoberta Baetta, Alberto Corsini
Current Medical Research and Opinion|June 21, 2011
Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?Alberto Corsini, Richard Ceska
Giornale Italiano Di Cardiologia (2006)|December 24, 2014
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk]Nicola Ferri, Alberto Corsini
Pageof 20

Showing results (1-10 of 200) with videos related to

Sort By:
Pageof 20
Cardiovascular Drugs and Therapy|February 3, 2006
Statin-related muscle complaints: an underestimated riskAlberto Corsini
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 6, 2019
Statin-associated muscle symptoms: is Proprotein convertase subtilisin/kexin type 9 inhibitors a therapeutic option?Alberto Corsini
Expert Opinion on Pharmacotherapy|April 16, 2025
Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidenceAlberto Corsini
Cardiovascular Drugs and Therapy|October 24, 2003
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular riskAlberto Corsini
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 22, 2016
Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events: the importance of keeping constant low cholesterol levelsAlberto Corsini
Renal Failure|June 17, 2005
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantationAlberto Corsini, Hallvard Holdaas
Journal of Clinical Pharmacology|February 26, 2013
Drug-induced liver injury: the role of drug metabolism and transportAlberto Corsini, Michele Bortolini
Drugs|August 5, 2011
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differencesRoberta Baetta, Alberto Corsini
Current Medical Research and Opinion|June 21, 2011
Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?Alberto Corsini, Richard Ceska
Giornale Italiano Di Cardiologia (2006)|December 24, 2014
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk]Nicola Ferri, Alberto Corsini
Pageof 20